Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip Camilleri

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Clinical and Translational Radiation Oncology|January 15, 2026
Salvage stereotactic MR-Guided adaptive radiotherapy (SMART) re-irradiation for locally recurrent prostate Cancer: Clinical and dosimetric outcomesElena Moreno-Olmedo, Dan Murray, Ben George, et al.
Physics and Imaging in Radiation Oncology|January 9, 2026
Isotoxic stereotactic reirradiation for recurrent pelvic cancersChristopher J H Pagett, John Lilley, Christopher O'Hara, et al.
Advances in Radiation Oncology|November 10, 2025
Safety and Efficacy of Stereotactic Magnetic Resonance-Guided Adaptive Radiation Therapy (SMART) for Ultracentral Metastases in Non-Small Cell Lung CancerElena Moreno-Olmedo, Ben George, Kasia Owczarczyk, et al.
Clinical and Translational Radiation Oncology|March 7, 2024
Factors influencing local control after MR-guided stereotactic body radiotherapy (MRgSBRT) for adrenal metastasesGamze Ugurluer, Famke L Schneiders, Stefanie Corradini, et al.
Radiation Oncology (London, England)|August 22, 2022
Clinical adoption patterns of 0.35 Tesla MR-guided radiation therapy in Europe and AsiaBerend J Slotman, Mary Ann Clark, Enis Özyar, et al.
JU Open Plus|March 12, 2026
Flourine-18 Prostate-Specific Membrane Antigen-1007 Positron Emission Tomography Imaging in Staging of Primary and Secondary Prostate Cancer-A Retrospective Observational Cohort StudyMatthew H V Byrne, Nithesh Ranasinha, Abhishek Sharma, et al.
The New England Journal of Medicine|October 16, 2024
Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate CancerNicholas van As, Clare Griffin, Alison Tree, et al.
The Lancet. Oncology|September 16, 2022
Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trialAlison C Tree, Peter Ostler, Hans van der Voet, et al.
The Lancet. Oncology|September 22, 2019
Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trialDouglas H Brand, Alison C Tree, Peter Ostler, et al.
BJU International|February 26, 2026
The PRAGMATIC pathway - PRostate cancer diAGnosis and MAnagement Triage In Clinical careAbhishek Sharma, Teresa Campbell, Sagar Kanabar, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Clinical and Translational Radiation Oncology|January 15, 2026
Salvage stereotactic MR-Guided adaptive radiotherapy (SMART) re-irradiation for locally recurrent prostate Cancer: Clinical and dosimetric outcomesElena Moreno-Olmedo, Dan Murray, Ben George, et al.
Physics and Imaging in Radiation Oncology|January 9, 2026
Isotoxic stereotactic reirradiation for recurrent pelvic cancersChristopher J H Pagett, John Lilley, Christopher O'Hara, et al.
Advances in Radiation Oncology|November 10, 2025
Safety and Efficacy of Stereotactic Magnetic Resonance-Guided Adaptive Radiation Therapy (SMART) for Ultracentral Metastases in Non-Small Cell Lung CancerElena Moreno-Olmedo, Ben George, Kasia Owczarczyk, et al.
Clinical and Translational Radiation Oncology|March 7, 2024
Factors influencing local control after MR-guided stereotactic body radiotherapy (MRgSBRT) for adrenal metastasesGamze Ugurluer, Famke L Schneiders, Stefanie Corradini, et al.
Radiation Oncology (London, England)|August 22, 2022
Clinical adoption patterns of 0.35 Tesla MR-guided radiation therapy in Europe and AsiaBerend J Slotman, Mary Ann Clark, Enis Özyar, et al.
JU Open Plus|March 12, 2026
Flourine-18 Prostate-Specific Membrane Antigen-1007 Positron Emission Tomography Imaging in Staging of Primary and Secondary Prostate Cancer-A Retrospective Observational Cohort StudyMatthew H V Byrne, Nithesh Ranasinha, Abhishek Sharma, et al.
The New England Journal of Medicine|October 16, 2024
Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate CancerNicholas van As, Clare Griffin, Alison Tree, et al.
The Lancet. Oncology|September 16, 2022
Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trialAlison C Tree, Peter Ostler, Hans van der Voet, et al.
The Lancet. Oncology|September 22, 2019
Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trialDouglas H Brand, Alison C Tree, Peter Ostler, et al.
BJU International|February 26, 2026
The PRAGMATIC pathway - PRostate cancer diAGnosis and MAnagement Triage In Clinical careAbhishek Sharma, Teresa Campbell, Sagar Kanabar, et al.
Pageof 2